

ASX Announcement

Race appoints Dr David Fuller Chief Medical Officer

- Former Senior Vice President of Clinical Development at Syneos Health
- Dr Fuller brings over 30 years' experience in oncology, international markets, listed businesses and is a highly experienced pharmaceutical physician
- Appointment follows an intensive two-month recruitment process to find a CMO of appropriate calibre and experience

20 April 2021 – Race Oncology Limited (“Race”) is pleased to announce the appointment of Dr David Fuller as Chief Medical Officer (CMO). This appointment follows the announcement by Race on 19 February 2021 that the Company would be recruiting a full-time, Australian-based CMO to drive its three-pillar strategy forward.

An internationally experienced biopharmaceutical executive and physician, Dr Fuller brings a deep understanding of the successful development & commercialisation of novel pharmaceuticals. His 30 years of R&D experience spans large, mid and small cap companies including pre-clinical and clinical development, medical and regulatory affairs, and commercialisation.

Dr Fuller will join Race Oncology on 1 July 2021 from Syneos Health Clinical Solutions, where he has been the Senior Vice President of Clinical Development in the Oncology Business Unit. Dr Fuller also currently serves as Chairman for EpiAxis Therapeutics, a privately owned epigenetic therapeutic and diagnostic company, and is a Non-Executive Director of the ASX-listed biotech company, AdAlta (ASX: 1AD).

Dr Fuller was formerly a Director at Linear Clinical Research, Chairman of Dimerix Bioscience, CMO/COO at Trident Clinical Research, CMO at Arana Therapeutics, and Vice-President Clinical at Genzyme Europe.

During his career, he has directly led successful major market drug approvals including Moraxen (UK), Busulfex (US Paediatrics and EU Adult indications), Xyrem (US) and Renagel (EU). He has also designed and executed multiple Phase I, II and III studies (US, EU, Asia) for both orphan and non-orphan drug products.

Commenting on the new appointment, Race Oncology CEO and Managing Director, Phil Lynch said, *“This is an important appointment for Race as David brings significant experience and capability. David has been successful in developing a number of pharmaceutical products across various international markets and we look forward to his future guidance in optimising plans for the execution of our Three Pillar strategy and maximising the significant opportunities we have ahead for Bisantrone.”*

Dr Fuller said, *“I am honoured and excited to be joining Race at such a critical time in the Company’s evolution given the huge potential of Bisantrone as both a targeted precision oncology drug and a differentiated chemotherapeutic. I look forward to applying my experience*



and expertise to help Race successfully realise the objectives of its three-pillar strategy. And I am pleased to have a new opportunity to again work with Professor Borje Anderson after our successful prior collaboration on Busulfex”.

Dr Fuller holds a Bachelor of Medicine / Bachelor of Surgery degree, and a Bachelor of Pharmacy (First Class Honours in Pharmacology), both from University of Sydney. He is also a Member of the American Society Clinical Oncology (ASCO).

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase II/III cancer drug called Bisantrene.

Bisantrene is a potent inhibitor of the Fat mass and obesity associated (FTO) protein. Over-expression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Bisantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers. The Company also has compelling clinical data for the use of Bisantrene as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), breast and ovarian cancers and is investigating its use in these areas.

Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy for the clinical development of Bisantrene.

See more at www.raceoncology.com.

Release authorised by:

Phil Lynch, CEO/MD on behalf
of the Race Board of Directors
phillip.lynch@raceoncology.com

Media contact:

Jane Lowe
+61 411 117 774
jane.lowe@irdepartment.com.au